[1] 刘宗超，李哲轩，张阳，等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2021，7(2)：1-14.
[2] LAW C L,CERVENY C G,GORDON K A,et al.Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates[J].Clin Cancer Res,2004,10(23):7842-7851.
[3] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[4] ROUPRET M,BABJUK M,BURGER M,et al.European Association of Urology Guidelines on upper urinary tract urothelial carcinoma：2020 update[J].Eur Urol,2021,79(1):62-79.
[5] TREGUNNA R.Combination treatment in advanced urothelial carcinoma[J].Nat Rev Urol,2021,18(7):383.
[6] LALANI A A，SONPAVDE G P.Systemic treatments for metastatic urothelial carcinoma[J].Expert Opin Pharmacother,2019,20(2):201-208.
[7] ROBERT J T，MAASE V，Sengelov L，et al.Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer[J].Ann Oncol,2006,17(Supl 5):118-122.
[8] MAASE H,SENGELOV L，ROBERTS J T，et al.Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin,with methotrexate,vinblastine,doxorubicin,plus cisplatin in patients with bladder cancer[J].J Clin Oncol,2005,23(21):4602-4608.
[9] 曾弘烨，宁文静，罗文新.ADC药物的抗体组成及其作用靶点研究进展[J].中国生物工程杂志,2022,42(5):69-80.
[10] JIN Y M,SCHLADETSCH M A,HUNG X T,et al.Stepping forward in antibody-drug conjugate development[J].Pharmacol Ther,2022,229:107917.
[11] MAHMOOD I.Clinical pharmacology of antibody-drug conjugates[J].Antibodies (Basel),2021,10(2):20.
[12] STREBHARDT K,ULLRICH A.Paul Ehrlich's magic bullet concept:100 years of progress[J].Nat Rev Cancer,2008,8(6):473-480.
[13] FU Z,LI S,HAN S,et al.Antibody drug conjugate:the “biological missile” for targeted cancer therapy[J].Signal Transduct Target Ther,2022,7(1):93.
[14] BECK A,GOETSCH L,DUMONTET C,et al.Strategies and challenges for the next generation of antibody-drug conjugates[J].Nat Rev Drug Discov,2017,16(5):315-337.
[15] ALLEY S C,OKELEY N M,SENTER P D.Antibody-drug conjugates:targeted drug delivery for cancer[J].Curr Opin Chem Biol,2010,14(4):529-537.
[16] XU S.Internalization,trafficking,intracellular processing and actions of antibody-drug conjugates[J].Pharm Res,2015,32(11):3577-3583.
[17] GRANSETH B,ODERMATT B,ROYLE S J,et al.Clathrin-mediated endocytosis:the physiological mechanism of vesicle retrieval at hippocampal synapses[J].J Physiol,2007,585(3):681-686.
[18] SMITH L M,NESTEROVA A,ALLEY S C,et al.Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97[J].Mol Cancer Ther,2006,5(6):1474-1482.
[19] JEDEMA I,BARGE R M,VELDEN V H J et al.Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin:rationale for efficacy in CD33-negative malignancies with endocytic capacity[J].Leukemia,2004,18(2):316-325.
[20] SCHRAMA D,REISFELD R A,BECKER J C.Antibody targeted drugs as cancer therapeutics[J].Nat Rev Drug Discov,2006,5(2):147-159.
[21] LAW C L,GORDON K A,TOKI B E,et al.Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates[J].Cancer Res,2006,66(4):2328-2337.
[22] LAW C L,CHARLES G C,GORDON K A,et al.Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates[J].Clin Cancer Res,2004,10(23):7842-7851.
[23] CHATTERJEE S,SINHA S,KUNDU C N.Nectin cell adhesion molecule-4 (NECTIN-4):a potential target for cancer therapy[J].Eur J Pharmacol,2021,911:174516.
[24] TEO M Y,ROSENBERG J E.NECTIN4 heterogeneity and molecular diversity in bladder cancers:deconstructing the activity of an antibody-drug conjugate[J].Clin Cancer Res,2021,27(18):4950-4952.
[25] WONG J L,RONSENBERG J E.Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma[J].Expert Opin Biol Ther,2021,21(7):863-873.
[26] RONSENBERG J,SRIDHAR S S,ZHANG J,et al.EV-101:a phase Ⅰ study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors,including metastatic urothelial carcinoma[J].J Clin Oncol,2020,38(10):1041-1049.
[27] YU E Y,PETRYLAK D P,O'DONNELL P H,et al.Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201):a multicentre,single-arm,phase 2 trial[J].Lancet Oncol,2021,22(6):872-882.
[28] POWLES T,ROSENBERG J E,SONPAVDE G P,et al.Enfortumab vedotin in previously treated advanced urothelial carcinoma[J].N Engl J Med,2021,384(12):1125-1135.
[29] ZHANG X,HUANG A C,CHEN F,et al.Novel development strategies and challenges for anti-Her2 antibody-drug conjugates[J].Antib Ther,2022,5(1):18-29.
[30] NINI A,HOFFMANN M J,LAMPIGNANO R,et al.Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells[J].Cytometry B Clin Cytom,2020,98(4):355-367.
[31] XU Y,WANG Y,GONG J,et al.Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors[J].Gastric Cancer,2021,24(4):913-925.
[32] DE BONO J S,CONCIN N,HONG D S,et al.Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201):a first-in-human,multicentre,phase 1-2 trial[J].Lancet Oncol,2019,20(3):383-393.
[33] AKBARI B,FARAJNIA S,AHDI K S,et al.Immunotoxins in cancer therapy:review and update[J].Int Rev Immunol,2017,36(4):207-219.
[34] LIPINSKI M,PARKS D R,ROUSE R V,et al.Human trophoblast cell-surface antigens defined by monoclonal antibodies[J].Proc Natl Acad Sci U S A,1981,78(8):5147-5150.
[35] AVELLINI C,LICINI C,LAZZARINI R,et al.The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer[J].Oncotarget,2017,8(35):58642-58653.
[36] TAGAWA S T,BALAR A V,PETRYLAK D P,et al.TROPHY-U-01:a phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors[J].J Clin Oncol,2021,39(22):2474-2485.
[37] OH D Y,BANG Y J.HER2-targeted therapies-a role beyond breast cancer[J].Nat Rev Clin Oncol,2020,17(1):33-48.
[38] MOSKOWITZ C H,ANDRES F T,SHAH B D,et al.Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage non-Hodgkin lymphoma[J].Blood,2014,124 (21):1741.
[39] SPIZZO G,FONG D,WURM M,et al.EpCAM expression in primary tumour tissues and metastases:an immunohistochemical analysis[J].J Clin Pathol,2011,64(5):415-420.
[40] SUN X,MARTIN R C G,ZHENG Q.et al.Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma[J].Cell Oncol,2018,41:651-662.
[41] KOWALSKI M,ENTWISTLE J,CIZEAU J,et al.A phase Ⅰ study of an intravesically administered immunotoxin targeting EpCam for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and Bcg-intolerant patients[J].Drug Des Devel Ther,2010,4:313-320.
[42] KOWALSKI M,GUINDON J,BRAZAS L,et al.A phase Ⅱ study of oportuzumab monatox:an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin[J].J Urol,2012,188(5):1712-1718. |
